CD33
Myeloid cell surface antigen CD33
As of the edition of 20 October 2026, CD33 (myeloid cell surface antigen CD33, UniProt P20138) has 11 drugs tested at it and 9 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20138
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 11
- Disease areas
- Blood and lymph; Cancer; Inherited and neonatal; Immune system; Heart and blood vessels
- Registered trials of its drugs
- 127
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Gemtuzumab ozogamicin | Marketed | Phase 4 | Ends 2029 |
| Lintuzumab | Stopped | Phase 3 | none listed |
| BI 836858 | Stopped | Phase 3 | none listed |
| Lintuzumab actinium ac-225 | Stopped | Phase 2 | none listed |
| Vadastuximab talirine | Went quiet | Phase 3 | none listed |
| Gemtuzumab | Marketed | Phase 4 | none listed |
| AVE-9633 | Stopped | Phase 1 | none listed |
| BMS-986497 | Active | Phase 1 | none listed |
| CC-96191 | Stopped | Phase 1 | none listed |
| GEM333 | Stopped | Phase 1 | none listed |
| JNJ-67571244 | Status not established | Phase 1 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Sanofi | Route A |
| Beat AML | Route A |
| Boehringer Ingelheim | Route A |
The other 6 companies at CD33
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at CD33, ranked, with the facts behind eachRequest access. Nothing is shown until you do.